Status:
COMPLETED
A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Urinary Incontinence
Eligibility:
FEMALE
40-74 years
Phase:
PHASE2
Brief Summary
Overactive bladder is very prevalent in postmenopausal women. The current study is designed to investigate whether a new drug may offer safe and effective treatment.
Detailed Description
Clinical development of MK-0634 was discontinued. Study MK-0634-027 was a safety follow-up study to determine if there were any ocular effects of MK-0634 in participants from the United Kingdom who we...
Eligibility Criteria
Inclusion
- Postmenopausal females (ages 40-74) with predominantly urge urinary incontinence overactive bladder episodes.
- Patients must meet minimum eligibility requirements (e.g., average number of micturitions/day) based on screening diary cards.
Exclusion
- Patients must not suffer from diabetes insipidus
- Hyperglycemia
- Hypercalcemia
- Orthostatic hypotension
- Active/recurrent urinary tract infections (\>6 episodes per year)
- Patients must be willing to discontinue their current OAB medication therapy.
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2006
Estimated Enrollment :
848 Patients enrolled
Trial Details
Trial ID
NCT00231790
Start Date
August 1 2005
End Date
October 1 2006
Last Update
December 17 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.